Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

References

• Crump JA. Progress in typhoid fever epidemiology. Clin Infect Dis. 2019;68(Supplement_1):S4–9. doi:10.1093/cid/ciy846.
   PubMedGoogle Scholar
• Pitzer VE, Meiring J, Martineau FP, Watson CH, Kang G, Basnyat B, Baker S. The invisible burden: diagnosing and combatting typhoid fever in Asia and Africa. Clin Infect Dis. 2019;69(Supplement_5):S395–401. doi:10.1093/cid/ciz611.
   PubMedGoogle Scholar
• Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, Andrews JR, Bhutta ZA, Crump JA, Im J. et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the global burden of disease study 2017. Lancet Infect Dis. 2019;19(4):369–81. doi:10.1016/S1473-3099(18)30685-6.
   PubMed Web of Science ®Google Scholar
• Lee J-S, Mogasale VV, Mogasale V, Lee K. Geographical distribution of typhoid risk factors in low and middle income countries. BMC Infect Dis. 2016;16:732. doi:10.1186/s12879-016-2074-1.
   PubMed Web of Science ®Google Scholar
• John J, Van Aart CJ, Grassly NC, Baker S. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PloS Negl Trop Dis. 2016;10(4):e0004616. doi:10.1371/journal.pntd.0004616.
   PubMed Web of Science ®Google Scholar
• Barkume C, Date K, Saha SK, Qamar FN, Sur D, Andrews JR, Luby SP, Khan MI, Freeman A, Yousafzai MT. et al. Phase I of the surveillance for enteric fever in Asia project (SEAP): an overview and lessons learned. J Infect Dis. 2018;218(suppl_4):S188–94. doi:10.1093/infdis/jiy522.
   PubMedGoogle Scholar
• Andrews JR, Vaidya K, Bern C, Tamrakar D, Wen S, Madhup S, Shrestha R, Karmacharya B, Amatya B, Koju R. et al. High rates of enteric fever diagnosis and lower burden of culture-confirmed disease in Peri-urban and rural Nepal. J Infect Dis. 2018;218(suppl_4):S214–21. doi:10.1093/infdis/jix221.
   PubMedGoogle Scholar
• Garrett DO, Longley AT, Aiemjoy K, Yousafzai MT, Hemlock C, Yu AT, Vaidya K, Tamrakar D, Saha S, Bogoch II. et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the surveillance for enteric fever in Asia project. Lancet Glob Health. 2022;10:e978–88. doi:10.1016/S2214-109X(22)00119-X.
   PubMed Web of Science ®Google Scholar
• Khanal B, Sharma SK, Bhattacharya SK, Bhattarai NR, Deb M, Kanungo R. Antimicrobial susceptibility patterns of Salmonella enterica serotype typhi in eastern Nepal. J Health Popul Nutr. 2007;25:82–7.
   PubMed Web of Science ®Google Scholar
• Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S. et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86:260–8. doi:10.2471/BLT.06.039818.
   PubMed Web of Science ®Google Scholar
• Bhetwal A, Maharjan A, Khanal PR, Parajuli NP. Enteric fever caused by Salmonella enterica Serovars with reduced susceptibility of fluoroquinolones at a community based teaching hospital of Nepal. Iran J Pediatr Hematol Oncol. 2017;2017:1–6. doi:10.1155/2017/2869458.
   Google Scholar
• Britto CD, Wong VK, Dougan G, Pollard AJ, Kang G. A systematic review of antimicrobial resistance in Salmonella enterica serovar typhi, the etiological agent of typhoid. PloS Negl Trop Dis. 2018;12(10):e0006779. doi:10.1371/journal.pntd.0006779.
   PubMed Web of Science ®Google Scholar
• Qamar FN, Yousafzai MT, Dehraj IF, Shakoor S, Irfan S, Hotwani A, Hunzai MJ, Thobani RS, Rahman N, Mehmood J. et al. Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019. Clin Infect Dis. 2020;71:S276–84. doi:10.1093/cid/ciaa1323.
   PubMed Web of Science ®Google Scholar
• Masuet-Aumatell C, Atouguia J. Typhoid fever infection – antibiotic resistance and vaccination strategies: a narrative review. Travel Med Infect Dis. 2021;40:101946. doi:10.1016/j.tmaid.2020.101946.
   PubMed Web of Science ®Google Scholar
• Brockett S, Wolfe MK, Hamot A, Appiah GD, Mintz ED, Lantagne D. Associations among water, sanitation, and hygiene, and food exposures and typhoid fever in case–control studies: a systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103(3):1020–31. doi:10.4269/ajtmh.19-0479.
   PubMed Web of Science ®Google Scholar
• WHO. Summary of the WHO position paper on typhoid vaccines: WHO position paper—March 2018. [ accessed 2022 Feb 17]. https://www.who.int/immunization/policy/position_papers/PP_typhoid_2018_summary.pdf.
   Google Scholar
• Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infect Dis. 2019;19(7):728–39. doi:10.1016/S1473-3099(18)30804-1.
   PubMed Web of Science ®Google Scholar
• WHO. Weekly epidemiological record. Typhoid vaccines: WHO position paper–March 2018. 2018. https://www.who.int/publications/i/item/typhoid-vaccines-who-position-paper-march-2018”.
   Google Scholar
• Jeon HJ, Pak GD, Im J, Owusu-Dabo E, Adu-Sarkodie Y, Gassama Sow A, Bassiahi Soura A, Gasmelseed N, Keddy KH, Bjerregaard-Andersen M. et al. Determining the best immunization strategy for protecting African children against invasive salmonella disease. Clin Infect Dis [Internet]. 2018; [accessed 2022 Feb 19]. doi:10.1093/cid/ciy386.
   PubMed Web of Science ®Google Scholar
• Syed KA, Saluja T, Cho H, Hsiao A, Shaikh H, Wartel TA, Mogasale V, Lynch J, Kim JH, Excler J-L. et al. Review on the recent advances on typhoid vaccine development and challenges ahead. Clin Infect Dis. 2020;71(Supplement_2):S141–50. doi:10.1093/cid/ciaa504.
   PubMedGoogle Scholar
• Sahastrabuddhe S, Saluja T. Overview of the typhoid conjugate vaccine pipeline: Current status and future plans. Clin Infect Dis. 2019;68(Supplement_1):S22–6. doi:10.1093/cid/ciy884.
   PubMedGoogle Scholar
• Qamar FN, Batool R, Qureshi S, Ali M, Sadaf T, Mehmood J, Iqbal K, Sultan A, Duff N, Yousafzai MT. Strategies to improve coverage of typhoid conjugate vaccine (TCV) immunization campaign in Karachi, Pakistan. Vaccines. 2020;8(4):697. doi:10.3390/vaccines8040697.
   Web of Science ®Google Scholar
• Jakobsen H, Jonsdottir I. Mucosal Vaccination Against Encapsulated Respiratory Bacteria - New Potentials for Conjugate Vaccines? Scand J Immunol. 2003;58:119–28. doi:10.1046/j.1365-3083.2003.01292.x.
   PubMed Web of Science ®Google Scholar
• Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq YG. et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381(23):2209–18. doi:10.1056/NEJMoa1905047.
   PubMed Web of Science ®Google Scholar
• Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, Tonks S, Mujadidi YF, O’Reilly P, Mazur O. et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021;9(11):e1561–8. doi:10.1016/S2214-109X(21)00346-6.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS, Kim YH, Park J, Jo S-K. et al. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children. Vaccine. 2018;36(26):3794–801. doi:10.1016/j.vaccine.2018.05.038.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS. et al. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study. EClinicalMedicine. 2020;27:100540. doi:10.1016/j.eclinm.2020.100540.
   PubMedGoogle Scholar
• Rai GK, Saluja T, Chaudhary S, Tamrakar D, Kanodia P, Giri BR, Shrestha R, Uranw S, Kim DR, Yang JS. et al. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Lancet Infect Dis. 2022;22(4):529–40. doi:10.1016/S1473-3099(21)00455-2.
   PubMed Web of Science ®Google Scholar
• Kundu R, Kandulna AK, Nayak U, Jangid SK, Babu TR, Vukkala R, Sharma S, Goyal VK, Daultani P, Mittal R. et al. Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial. Indian Pediatr. 2020;57(7):625–30. doi:10.1007/s13312-020-1890-y.
   PubMed Web of Science ®Google Scholar
• Lee EY, Park JY, Kim DR, Song M, Sahastrabuddhe S, Kim H, Chon Y, Yang JS, Darton TC. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT). PloS Negl Trop Dis. 2020;14(3):e0008171. doi:10.1371/journal.pntd.0008171.
   PubMed Web of Science ®Google Scholar
• Choi SK, Baik YO, Kim CW, Kim SK, Oh IN, Yoon H, Yu D, Lee C. An open-label, comparative, single dose, clinical phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults. Vaccine. 2021;39(19):2620–7. doi:10.1016/j.vaccine.2021.03.089.
   PubMed Web of Science ®Google Scholar
• Azmatullah A, Qamar FN, Thaver D, Zaidi AK, Bhutta ZA. Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever. J Glob Health. 2015;5(2):020407. doi:10.7189/jogh.05.020407.
   PubMed Web of Science ®Google Scholar
• Saluja T, Rai GK, Chaudhary S, Kanodia P, Giri BR, Kim DR, Yang JS, Park I-Y, Kyung S-E, Vemula S. et al. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants. Vaccine. 2022;40:5828–34. doi:10.1016/j.vaccine.2022.08.034.
   PubMed Web of Science ®Google Scholar